Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Neubase Therapeutics Inc (OQ:NBSE)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for NBSE*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 27, 2023 09:00 ET
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for...
Read full article
Sep 18, 2023 09:31 ET
Thinking about buying stock in Navios Maritime Holdings, Biodexa Pharmaceuticals, Iovance Biotherapeutics, Neubase Therapeutics, or Iris Energy?
NEW YORK, Sept. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NM, BDRX, IOVA, NBSE, and IREN.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.82
--
--
Price to Sales - TTM
--
4.68
3.32
Price to Book - most recent quarter
0.18
2.14
2.21
Price to Cash Flow per share - TTM
--
13.33
14.62
Price to Free Cash Flow per share - TTM
--
25.72
24.76
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company's programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington's disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.

See business summary

 

Twitter

Search (past week) for $NBSE

  • No tweets found